Idarucizumab for dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome

To the Editor  The recent European Heart Rhythm Association (EHRA) practical guidelines on the use of non-vitamin-K oral anticoagulants in patients with nonvalvular AF recommend administration of idarucizumab for life-threatening bleeding or prior to emergency surgery in dabigatran-treated patients. At the end of 2015, idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, was approved for use in Europe. In the context of the European guidelines, we would like to present our experience with the use of the specific reversal agent in everyday practice, indicating the important role of idarucizumab in the setting of surgery that cannot be delayed.

Dabigatran etexilate (dabigatran), a direct thrombin inhibitor, is commonly used for stroke prevention in patients with atrial fibrillation (AF), who can experience serious perioperative bleeding if the procedure is performed while on anticoagulation.

Acute aortic syndromes (AASs) are a common cause for emergency cardiac surgery associated with high mortality and morbidity. The REVERSE AD trial has shown that idarucizumab is efficacious in dabigatran reversal, and it was used in a single patient with aortic dissection (AD) in this trial. According to the study protocol, idarucizumab was administered preoperatively. We used idarucizumab intraoperatively in 2 dabigatran-treated patients with Stanford type A AAS.

An 83-year-old man with a history of ascending aortic aneurysm (AAA) complicated with AAS in form of Stanford type A intramural hematoma, was taking dabigatran due to AF (2 × 110 mg/d; last dose intake on the day of surgery). Comorbidities were chronic kidney disease (stage 3 CKD), arterial hypertension, prior ischemic stroke, peripheral arterial disease, and peptic ulcer disease. The diagnosis was confirmed with contrast-enhanced computed tomography. Preoperative laboratory findings, including dabigatran concentrations based on dilute thrombin time, are presented in Table 1. According to the Papworth Bleeding Risk Score, the bleeding risk was high (4 points).

Immediate surgery was executed using the same protocol (time from hospital admission until admission to the operating room was 98 minutes, there was no delay due to dabigatran therapy).
Dabigatran levels were measured using the Hemoclot thrombin inhibitor assay (HYPHEN BioMed, NeuvillesurOise, France), as described elsewhere. Baseline dabigatran level (during dabigatran treatment): 61–143 ng/ml.

**TABLE 1** Preoperative laboratory findings in patients with acute aortic syndrome and receiving dabigatran treatment (reference ranges are given in brackets)

<table>
<thead>
<tr>
<th>Patient, sex/age, y</th>
<th>RBC (4.2–6.0 ×10^6/µl)</th>
<th>HGB (14.0–18.0 g/dl)</th>
<th>HCT (40.0%–54.0%)</th>
<th>PLT (140–440 10^3/µl)</th>
<th>APTT (25.9–36.6 sec)</th>
<th>INR (0.9–1.3)</th>
<th>Creatinine (62–106 µmol/l)</th>
<th>eGFR (&gt;60 ml/min/1.73 m²)</th>
<th>Baseline dabigatran level, ng/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>M/83</td>
<td>3.36</td>
<td>10.4</td>
<td>31.2</td>
<td>129</td>
<td>77.8</td>
<td>1.74</td>
<td>264</td>
<td>19</td>
<td>209</td>
</tr>
<tr>
<td>M/76</td>
<td>5.31</td>
<td>15.3</td>
<td>47.3</td>
<td>115</td>
<td>48.3</td>
<td>1.46</td>
<td>185</td>
<td>30</td>
<td>84</td>
</tr>
</tbody>
</table>

Abbreviations: APTT, activated partial thromboplastin time; eGFR, estimated glomerular filtration rate; HCT, hematocrit; HGB, hemoglobin; INR, international normalized ratio; M, male; RBC, red blood cells; PLT, platelets

Upon opening of the pericardium, massive cardiac tamponade was apparent; however, a supracoronary ascending aortic and hemiarch replacement procedure was successfully performed. Idarucizumab was administered after CPB termination (5 g IV, in 1 infusion of 5-minute duration), and the control level of dabigatran was 36 ng/ml in the operating room. Severe low cardiac output syndrome has developed upon CPB cessation. A total of 10 units of platelet concentrate, 3 units of fresh frozen plasma, and 2 units of packed red blood cells were administered in the operating room, before chest closure, and massive isotropic support was required (epinephrine, 1 µg/kg/min; norepinephrine, 0.83 µg/kg/min; dobutamine, 10 µg/kg/min; milrinone, 0.42 µg/kg/min). Although intraoperative transesophageal echocardiography revealed normal aortic valve function and appropriately deaired left ventricle, severe cardiogenic shock developed and resistant hypertension was observed. Mechanical circulatory support was not feasible. Despite the treatment, the patient expired directly following the end of the procedure, in the operating room, without any apparent bleeding.

Our current report demonstrates that idarucizumab effectively reverses dabigatran in the setting of emergency cardiac surgery for AAS in patients with high plasma drug levels. One patient had a completely favorable outcome, and the other died due to heart failure. However, no major bleeding was observed in any of the presented cases, despite high preoperative bleeding risk (3–4 points in the Papworth Bleeding Risk Score) and high preoperative levels of dabigatran. Only blood product transfusions were needed, but no activated prothrombin complex concentrate or recombinant factor VII were necessary. Importantly, treatment with dabigatran did not delay any part of the cardiosurgical management, as idarucizumab was readily available on site.

The REVERSE AD trial demonstrated that idarucizumab rapidly and completely reverses dabigatran levels (in most patients they dropped by 99% and remained low for at least 12 hours; in some cases, an increase in dabigatran levels was observed after this time, probably secondary to drug redistribution from peripheral circulation); however, in individuals requiring an operation, it was administered before the surgery.

Our approach was slightly different, as a result of cardiac surgery-specific procedural characteristics. During an open heart surgery, coagulation is blocked anyway with heparin, and internal CPB suction is used to prevent blood loss. The rationale behind the choice of the idarucizumab administration timepoint was to provide the patient with dabigatran-free coagulation for as long postoperatively as possible. Dabigatran levels returned to normal in both cases. In the first patient, postoperative drainage was low, and bleeding was assessed as moderate—not more pronounced than in any other patient with AAS.

The important issue of necessary dabigatran treatment adjustment in individuals with renal failure warrants a comment, as both our patients suffered from CKD. The Cockcroft–Gault formula for creatinine clearance (CrCl) was employed in the RELY trial for the assessment of dabigatran eligibility and dosing. In AF patients aged 80 years or older, it has been demonstrated that 15% were ineligible for dabigatran based on CrCl of less than 30 ml/min, but the same patients would have been eligible if the the Modification of Diet in Renal Disease (MDRD) formula had been applied for the calculation of estimated glomerular filtration rate (eGFR); for those younger than 80 years, 5% would have received too high a dose of dabigatran. Thus, some patients (whose renal function is assessed based on eGFR with the MDRD formula) probably receive dabigatran despite excluding CKD or receive too high a dose. Furthermore, during CKD exacerbation, dabigatran should be stopped if there is any suspicion that the patient might need urgent surgery (as in a patient with known severe aortic dilation). That notwithstanding, our report demonstrates that salvage with idarucizumab is a bail-out option even in an dabigatran-overtreated individual with CKD exacerbation, who requires emergency cardiac surgery. No such option is available for patients treated with rivaroxaban or apixaban yet.

In our second patient, the fact of dabigatran intake was discovered after patient admission, during the emergency anesthesia workup. Emergency medicine personnel should be trained to obtain the information on dabigatran use and last intake from any patient with known AF and to pass this information to the tertiary care center. This approach is supported by the recent EHRA
Idarucizumab should be available in any tertiary cardiac and trauma center, where patients treated with dabigatran are likely to be managed. All physicians should be made aware which centers have idarucizumab at their disposal, and this information should be available at all times at any blood bank countrywide.

In conclusion, our report demonstrates that idarucizumab can facilitate successful cardio surgical treatment with a satisfactory hemostasis in the setting of AAS, in a patient treated with dabigatran. We believe that in the setting of cardiac surgery, the administration of idarucizumab intraoperatively (not preoperatively) is safe. The dose of 5 g IV in a rapid infusion administered upon CPB cessation may be a good therapeutic choice.

Acknowledgments The authors would like to thank Dr. Radosław Litwinowicz, MD, and Mr. Tadeusz Góralczyk, MSc, for their valuable contribution to patient management and preparation of the manuscript. This study was funded by a grant from the Jagiellonian University Medical College (No. K/ZDS/005695; to PM).

Author names and affiliations Piotr Mazur, Tomasz Darocha, Grzegorz Filip, Grzegorz Grudzień, Rafał Drwiła, Bogusław Kapelak (PM, GG, RD, BK: Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland; PM, GF, GG, BK: Department of Cardiovascular Surgery and Transplantology, John Paul II Hospital, Kraków, Poland; TD, RD: Department of Anesthesiology and Intensive Care, John Paul II Hospital, Kraków, Poland). PM and TD contributed equally to the work.

Corresponding author Piotr Mazur, MD, Instytut Kardiologii, Uniwersytet Jagielloński, Collegium Medicum, ul. Prądnicka 80, 31-202 Kraków, Poland, phone: +48 12 614 30 75, e-mail: piotr.k.mazur@gmail.com

Conflict of interest RD received lecture honoraria from Boehringer Ingelheim.


REFERENCES